Sign up to save your podcasts
Or
Share BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
Credit available for this activity expires: 3/21/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989323?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.2
2222 ratings
Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
Credit available for this activity expires: 3/21/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989323?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
JAMA Editors' Summary
127 Listeners
Medicine and Science from The BMJ
38 Listeners
The Bob Harrington Show
13 Listeners
NEJM This Week
314 Listeners
This Week in Cardiology
854 Listeners
JAMA Clinical Reviews
478 Listeners
AFP: American Family Physician Podcast
688 Listeners
One-on-One with Eric Topol
16 Listeners
Mayo Clinic Talks
283 Listeners
Frankly Speaking About Family Medicine
251 Listeners
The Curbsiders Internal Medicine Podcast
3,324 Listeners
JAMA Medical News
91 Listeners
Core IM | Internal Medicine Podcast
1,085 Listeners
Annals On Call Podcast
174 Listeners
The Clinical Problem Solvers
512 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
318 Listeners
Medicine and the Machine
59 Listeners
Keeping Current
8 Listeners
Run the List
245 Listeners
The Curious Clinicians
364 Listeners